| CD19 |
Pan-B cell (not plasma cells) |
B-ALL, B-cell lymphomas |
CAR-T (Tisagenlecleucel, Axicabtagene), Blinatumomab |
| CD20 |
Mature B-cells |
NHL (DLBCL, Follicular, MCL), CLL |
Rituximab, Obinutuzumab, Ofatumumab, Ibritumomab |
| CD22 |
Pre-B to mature B-cells |
B-ALL, B-cell lymphomas |
Inotuzumab ozogamicin |
| CD35 |
B-cells, dendritic cells |
Rarely therapeutic target |
None approved |
| CD3 |
Pan–T-cell marker |
Diagnostic in T-cell ALL/Lymphomas |
Not targeted directly (used in Blinatumomab as T-cell engager) |
| CD4 / CD8 |
Helper and cytotoxic T-cells |
T-cell lymphomas, immunophenotyping |
Not directly targeted, but checkpoint inhibitors (PD-1/PD-L1, CTLA-4) affect T-cell function |
| CD5 |
T-cells, subset of B-cells |
CLL/SLL, Mantle cell lymphoma |
Diagnostic marker (no direct therapy) |
| CD7 |
T-cells, NK cells |
T-cell ALL/lymphomas |
Investigational CAR-T |
| CD10 (CALLA) |
Pre-B cells, germinal center B-cells |
B-ALL, Follicular lymphoma, Burkitt lymphoma |
Diagnostic marker |
| CD13 / CD33 |
Myeloid lineage |
AML |
Gemtuzumab ozogamicin (anti-CD33 ADC) |
| CD30 |
Activated B- and T-cells |
Hodgkin lymphoma, ALCL |
Brentuximab vedotin (anti-CD30 ADC) |
| CD34 |
Hematopoietic stem/progenitor cells |
AML, ALL (diagnostic) |
No direct therapeutic targeting |
| CD38 |
Plasma cells, activated lymphocytes |
Multiple myeloma, CLL |
Daratumumab, Isatuximab |
| CD45 (LCA) |
All leukocytes |
Used in immunophenotyping |
Diagnostic only |
| CD52 |
Mature lymphocytes |
CLL, T-cell malignancies |
Alemtuzumab |
| CD56 |
NK cells, subset of T-cells |
NK/T-cell lymphoma, AML subset |
Diagnostic marker |
| CD70 |
Activated B- and T-cells |
Renal cell carcinoma, lymphomas |
Investigational (anti-CD70 mAbs, ADCs) |
| CD79a/b |
B-cell receptor components |
B-cell lymphomas, ALL |
Diagnostic marker |
| CD123 (IL-3Rα) |
Hematopoietic progenitors, plasmacytoid dendritic cells |
AML, BPDCN |
Tagraxofusp (anti-CD123 fusion protein) |
| CD138 (Syndecan-1) |
Plasma cells |
Multiple myeloma |
Diagnostic marker, CAR-T under study |
